Clinical studies consistently demonstrate that a single sub-psychomimetic dose of ketamine, an ionotropic glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist, produces fast-acting antidepressant responses in patients suffering from major depressive disorder, although the underlying mechanism is unclear 1-3 . Depressed patients report the alleviation of major depressive disorder symptoms within two hours of a single, low-dose intravenous infusion of ketamine, with effects lasting up to two weeks 1-3 , unlike traditional antidepressants (serotonin re-uptake inhibitors), which take weeks to reach efficacy. This delay is a major drawback to current therapies for major depressive disorder and faster-acting antidepressants are needed, particularly for suicide-risk patients 3 . The ability of ketamine to produce rapidly acting, long-lasting antidepressant responses in depressed patients provides a unique opportunity to investigate underlying cellular mechanisms. Here we show that ketamine and other NMDAR antagonists produce fast-acting behavioural antidepressant-like effects in mouse models, and that these effects depend on the rapid synthesis of brain-derived neurotrophic factor. We find that the ketamine-mediated blockade of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII), resulting in reduced eEF2 phosphorylation and de-suppression of translation of brain-derived neurotrophic factor. Furthermore, we find that inhibitors of eEF2 kinase induce fast-acting behavioural antidepressant-like effects. Our findings indicate that the regulation of protein synthesis by spontaneous neurotransmission may serve as a viable therapeutic target for the development of fast-acting antidepressants.
Clinical studies consistently demonstrate that a single sub-psychomimetic dose of ketamine, an ionotropic glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist, produces fast-acting antidepressant responses in patients suffering from major depressive disorder, although the underlying mechanism is unclear [1] [2] [3] . Depressed patients report the alleviation of major depressive disorder symptoms within two hours of a single, low-dose intravenous infusion of ketamine, with effects lasting up to two weeks 1-3 , unlike traditional antidepressants (serotonin re-uptake inhibitors), which take weeks to reach efficacy. This delay is a major drawback to current therapies for major depressive disorder and faster-acting antidepressants are needed, particularly for suicide-risk patients 3 . The ability of ketamine to produce rapidly acting, long-lasting antidepressant responses in depressed patients provides a unique opportunity to investigate underlying cellular mechanisms. Here we show that ketamine and other NMDAR antagonists produce fast-acting behavioural antidepressant-like effects in mouse models, and that these effects depend on the rapid synthesis of brain-derived neurotrophic factor. We find that the ketamine-mediated blockade of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII), resulting in reduced eEF2 phosphorylation and de-suppression of translation of brain-derived neurotrophic factor. Furthermore, we find that inhibitors of eEF2 kinase induce fast-acting behavioural antidepressant-like effects. Our findings indicate that the regulation of protein synthesis by spontaneous neurotransmission may serve as a viable therapeutic target for the development of fast-acting antidepressants.
We examined the acute effect of ketamine in wild-type C57BL/6 mice and detected notable behavioural responses in antidepressantpredictive tasks, including the forced swim test (FST), noveltysuppressed feeding (NSF) and learned helplessness (Supplementary Figs 1a-e and 2a-c) 4 . Ketamine also produced such responses in a sucrose consumption test, as well as in NSF and FST, after chronic mild stress, an animal model of depression ( Supplementary Fig. 1f-i) . To elucidate the mechanisms underlying the fast-acting antidepressant action of ketamine, we focused on FST, a test that is predictive of nonmonoaminergic antidepressant efficacy 4 . We examined the time course of behavioural antidepressant effects in wild-type mice after a single, low-dose treatment with ketamine, (5S,10R)-(1)-5-methyl-10,11-dihydro -5H-dibenzo(a,d)cyclohepten-5,10-imine maleate (MK-801) or 3-((R)-2-carboxypiperazin-4-yl)-prop-2-enyl-1-phosphonic acid (CPP) ( Fig. 1a-c) . After either 30 min or 3 h, each NMDAR antagonist markedly reduced the immobility of mice in FST, when compared to vehicle-treated animals, indicating that NMDAR blockade produces fast-acting antidepressant responses. Notably, in our system, acute treatment with conventional antidepressants did not produce antidepressant-like FST responses ( Supplementary Fig.  3 ), which may require multiple doses 5 treatment produced no alterations in hippocampal-dependent learning ( Supplementary Fig. 1d ) or locomotor activity ( Supplementary Fig.  4 ). These drugs have short half-lives (about 2-3 h) [6] [7] [8] , indicating that sustained NMDAR-antagonist-induced antidepressant responses are due to synaptic plasticity, not to persistent blockade of receptors.
Brain-derived neurotrophic factor (BDNF) is linked to traditional antidepressant action; BDNF expression in the hippocampus is increased by antidepressants 9 and BDNF deletion in the hippocampus attenuates antidepressant behavioural responses [10] [11] [12] . Moreover, intraventricular or intrahippocampal BDNF infusion causes rapid, sustained antidepressant-like effects, lasting 3-6 days in FST 13, 14 . To examine whether the antidepressant-like response to ketamine is mediated through BDNF, we administered ketamine to inducible Bdnf-knockout mice 10 , then observed FST behaviour. After 30 min, ketamine-treated wild-type littermate controls showed significant reductions in immobility, indicating antidepressant-like responses, when compared to vehicletreated controls ( Fig. 2a ). However, ketamine did not produce antidepressant-like effects in Bdnf-knockouts, indicating that fast-acting antidepressant responses require BDNF. After 24 h, ketamine significantly reduced immobility in controls, but not in Bdnf knockouts ( Fig. 2a ), indicating that ketamine's sustained effects depend on BDNF. To validate this link between NMDAR antagonists and BDNF-mediated antidepressant responses, MK-801 was administered to Bdnf knockouts or controls. After 30 min, MK-801 significantly reduced FST immobility in controls, but had no effect in Bdnf knockouts ( Supplementary Fig. 6 ). MK-801 did not affect FST behaviour after 24 h ( Supplementary Fig. 6 ), as previously demonstrated ( Fig. 1c ). We next generated postnatal conditional 15 knockouts in neurotrophic tyrosine kinase receptor, type 2 (Ntrk2, also called TrkB) and found that these mice were insensitive to ketamine's antidepressantlike effects in FST and NSF ( Supplementary Fig. 5a , b). To confirm TrkB engagement, we examined receptor autophosphorylation and found increased TrkB activation after NMDAR antagonist treatment ( Supplementary Fig. 5c ).
To determine whether NMDAR antagonists alter Bdnf expression in the hippocampus, wild-type mice were treated acutely with vehicle, ketamine or MK-801. Quantitative RT-PCR analysis of the coding exon of Bdnf showed that Bdnf mRNA expression was unaltered by ketamine or MK-801 at either 30 min or 24 h after treatment (Supplementary Fig. 7a ). Contrastingly, western blot and ELISA analyses showed that BDNF protein levels were markedly increased at 30 min, but not at 24 h, after NMDAR antagonist treatment ( Fig. 2b and Supplementary Fig. 7b ). Moreover, the acute effects of ketamine on BDNF extended to its precursor, proBDNF ( Supplementary Fig. 7c ). These data indicate that rapid increases in BDNF protein translation, not transcription, are necessary for fast-onset antidepressant responses. However, continued BDNF protein upregulation does not underlie ketamine's long-term behavioural effects.
To study further the roles of translation and transcription in ketamine's antidepressant-like effects, we examined FST behaviour in mice treated with the protein synthesis inhibitor anisomycin 16 or with the RNA polymerase inhibitor actinomycin D 17 , which block their respective processes by about 80% within 2 h. We pretreated mice with anisomycin or actinomycin D before treating them with ketamine ( Fig. 2c ). Anisomycin prevented the ketamine-induced rapid behavioural responses seen at 30 min in FST and NSF paradigms, indicating a dependence on new protein synthesis ( Fig. 2d and Supplementary Fig. 8a, b ). Anisomycin also prevented ketamine's long-term effect on FST (24 h), indicating that rapid protein translation was involved in sustained antidepressant-like responses ( Fig. 2e ). We found that the synthesis of both mature BDNF and proBDNF in the hippocampus was sensitive to anisomycin treatment ( Supplementary Fig. 8c, d ). However, actinomycin D did not affect ketamine's antidepressant-like effect on FST at either time point, indicating that it is independent of new gene expression ( Supplementary Fig. 9b , c). To confirm that actinomycin D crossed the blood-brain barrier, we examined Bdnf mRNA expression 
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in drug-treated animals and found decreased Bdnf transcription in the hippocampus ( Supplementary Fig. 9a ). Taken together, these findings indicate that rapid, transient translation of BDNF is required for ketamine's fast-acting and long-lasting antidepressant-like behavioural effects and that long-term antidepressant responses may be due to alterations in synaptic plasticity, initiated by transient increases in BDNF translation. We observed increased levels of BDNF protein in the cortex, but not in the nucleus accumbens, 30 min after acute administration of ketamine or MK-801 ( Supplementary Fig. 10a, b ). We further investigated whether NMDAR antagonism affected proteins other than BDNF. We found an increased level of activity-regulated cytoskeletal-associated protein (ARC) in the hippocampus (sensitive to anisomycin treatment; Supplementary Fig. 8e ) but there was no increase in HOMER or GRIA1 (also known as GLUR1), nor in the phosphorylation of ribosomal protein s6 kinase ( Supplementary Fig. 10c-f ). Additionally, these proteins remained unaltered in the cortex after acute treatment with NMDAR antagonists ( Supplementary Fig. 11a-e ).
Synaptic plasticity and ensuing learning processes are often mediated by NMDAR-activation-driven protein translation, but antidepressant-like effects require protein translation induced by NMDAR blockade. To resolve this paradox, we turned to recent evidence that NMDAR blockade by MK-801 or 2-amino-5-phosphonopentanoic acid (AP5) without neuronal activity, augments protein synthesis through eEF2 dephosphorylation (activation). eEF2 is a critical catalytic factor for ribosomal translocation during protein synthesis 18 . In this model, resting NMDAR activity causes sustained activation of eEF2 kinase (eEF2K, or CamKIII), which phosphorylates eEF2, effectively halting translation, whereas acute NMDAR blockade at rest (in the absence of action potentials) attenuates eEF2 phosphorylation, allowing the translation of target transcripts.
To evaluate this model, we tested whether excess synaptic glutamate, possibly elicited by NMDAR blockade, was responsible for the behavioural effects of ketamine. Acute NMDA administration did not alter FST behaviour (Fig. 2f ), as previously demonstrated 19 , but it increased ARC expression ( Supplementary Fig. 10i ), indicating that excess glutamate does not elicit rapid behavioural antidepressant effects. To define the role of neuronal activity in antidepressant behavioural effects, we tested whether NBQX, a blocker of a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) channels that reduces neuronal activity, or picrotoxin, a blocker of GABA (c-aminobutyric acid) channels that increases activity, affected FST behaviour 4, 20 . Acute systemic treatment with these drugs did not affect FST behaviour ( Fig. 2g ) or BDNF synthesis, though picrotoxin enhanced ARC expression in the hippocampus ( Supplementary Fig. 10g , h). However, when co-applied with ketamine, NBQX abolished behavioural antidepressant-like responses in FST ( Fig. 2h ), as previously described 4 . These data indicate that behavioural antidepressant effects are not elicited by alterations in evoked neurotransmission, but require ketamine-mediated augmentation of AMPA-receptor activation.
Recent evidence indicates that cortical mTOR signalling underlies ketamine-mediated antidepressant responses 21 . We investigated whether the rapid behavioural antidepressant effects of ketamine required mTOR activation, and whether this signalling was downstream of BDNF. Regulation of phosphorylated mTOR was not detected after acute administration of ketamine in control or Bdnf-knockout hippocampal tissue (Fig. 2i ), nor in wild-type cortical tissue ( Supplementary  Fig. 11d ). In earlier work, rapamycin prevented ketamine-mediated antidepressant responses; however, the link between rapamycin and antidepressant-like effects is equivocal 22 . We tested whether pre-treatment with rapamycin could block acute ketamine-mediated FST behaviour. Thirty minutes after ketamine administration, wild-type mice showed antidepressant responses unaffected by rapamycin treatment ( Supplementary Fig. 11h ). Rapamycin reduced the phosphorylation of ribosomal protein s6 kinase in the cortex and hippocampus (Supplementary Fig. 11f, g) , indicating that the rapamycin had penetrated brain tissue. The earlier study examined molecular effects 2 h after drug treatment, or behavioural effects 24 h after drug treatment 21 ; therefore mTOR's role in the antidepressant effect of ketamine may be one of maintenance rather than rapid induction. Representative field-potential traces (average 2 min) are shown during baseline (1) and at 45 min (2) . The asterisk refers to significantly different fieldpotential values (*, P , 0.05). For statistical analysis, we used two-way repeated ANOVA with Bonferroni post hoc analysis. The drug-time interaction was significant (F (143,1430) 5 6.723, P , 0.001).
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To determine whether ketamine inhibits NMDA-receptormediated spontaneous miniature excitatory postsynaptic currents (NMDAR-mEPSCs) 3, 24 when at rest, and whether it regulates eEF2 phosphorylation, we tested its impact on hippocampal neurons in vitro. After ketamine perfusion (1 mM, 5 mM or 50 mM), we recorded NMDAR-mEPSCs ( Fig. 3c ) and detected a significant decrease within minutes, similar to the effect of AP5 (ref. 23 ). Moreover, protein extracts from ketamine-treated neurons showed decreased eEF2 phosphorylation compared to vehicle-treated cultures, indicating that ketamine, in the absence of neuronal activity, dose-dependently leads to eEF2 de-phosphorylation, permitting protein synthesis (Fig. 3a, b) . Additionally, we evaluated ketamine's effects on hippocampal field potentials. Acute application of ketamine (20 mM, at rest) potentiated the synaptic responses subsequently evoked in hippocampal slices (Fig. 3e ), further showing that increased AMPA-mediated neurotransmission underlies ketamine's antidepressant-like behavioural effects. This result is consistent with findings regarding BDNF-dependent and protein-synthesis-dependent synaptic plasticity 25 .
To examine whether the fast-acting antidepressant response is mediated via eEF2, we administered ketamine or MK-801 to wild-type mice and analysed eEF2 phosphorylation. Within 30 min, ketamine and MK-801 led to rapid decreases in the level of phosphorylated eEF2 in the hippocampus (Fig. 4a-c and Supplementary Figs 12 and 13) , detected by immunostaining and western blot analysis (Fig. 4d ). However, cortical levels of phosphorylated eEF2 were unaltered after acute NMDAR-antagonist treatment ( Supplementary Fig. 11f ). To examine whether eEF2K inhibition alters BDNF protein expression in vivo, the eEF2K inhibitors rottlerin or 1-hexadecyl-2-methyl-3-(phenylmethyl)-1H-imidazolium iodide (NH125) were administered to wild-type mice and the mice were killed 30 min later. Rottlerin and NH125 produced significantly increased BDNF protein expression ( Fig. 4e, g) , with corresponding significant decreases in phosphorylated eEF2 in the hippocampus (Fig. 4f, h) . To assess directly whether eEF2K inhibition is sufficient to mediate fast-acting antidepressantlike responses, wild-type mice were treated with rottlerin or NH125 and then examined in FST. Both rottlerin and NH125 produced significant decreases in FST immobility at 30 min (Fig. 4i ), a timescale similar to that of the effects of NMDAR antagonists, indicating that fast-acting behavioural effects are mediated through eEF2K inhibition. To test whether mitogen-activated protein kinase (MAPK), a regulator of protein translation during neural activity, affects FST behaviour, we treated wild-type mice with the inhibitor SL327. This treatment reduced MAPK phosphorylation in hippocampal tissue (Supplementary Fig. 10j ), but did not affect FST behaviour (Fig. 4i ), indicating that antidepressant-like effects are specific to eEF2K inhibition during resting spontaneous glutamatergic signalling. We found that an acute dose of rottlerin or NH125 did not affect locomotor activity, but that antidepressant-related behavioural effects were long-lasting (Supplementary Fig. 14a-f ). To validate the finding that antidepressant effects after eEF2K inhibition were mediated through BDNF, we administered rottlerin to Bdnf-knockout mice and tested FST behaviour. Like NMDAR antagonists, rottlerin was ineffective in Bdnf knockouts, showing that increased Bdnf expression upon eEF2K inhibition is required to produce antidepressant-like behavioural responses ( Fig. 4j) .
Our data support the hypothesis that ketamine produces rapidly acting antidepressant-like behavioural effects through inhibition of spontaneous NMDAR-mEPSCs, leading to decreased eEF2K activity, thus permitting rapid increases in BDNF translation ( Supplementary  Fig. 15 ) which may, in turn, exert strong influences on presynaptic or e-h, Densitometric analyses of BDNF and p-eEF2. Significant increases are seen in hippocampal BDNF protein levels (normalized to GAPDH) with rottlerin (5 mg kg 21 ) versus vehicle (e), and with NH125 (5 mg kg 21 ) versus vehicle (g) (t-tests, *, P , 0.05). Significant decreases are seen in p-eEF2 (normalized to total eEF2) with rottlerin versus vehicle (f) and NH125 versus vehicle (h) (t-tests, *, P , 0.05). i, Immobility in FST of wild-type mice given acute rottlerin (5 mg kg 21 ) or NH125 (5 mg kg 21 ). ANOVA F (3,44) 5 8.13, P 5 0.0002 for treatment; Bonferroni post hoc analysis shows significance with rottlerin or NH125 versus vehicle (*, P , 0.05), but not with the MAPK inhibitor SL327 (10 mg kg 21 ). j, Immobility of Bdnf-knockout mice or littermate controls given acute rottlerin (5 mg kg 21 ) and tested 30 min later in FST. ANOVA F (1,19) 5 5.77, P 5 0.0267 for treatment; Bonferroni post hoc analysis for rottlerin versus vehicle-treated controls (*, P , 0.05; n 5 5-7 per group).
RESEARCH LETTER
postsynaptic efficacy 26, 27 . We found that fast-acting antidepressantlike effects cannot be elicited by disinhibition of behavioural circuitry, or by evoked neurotransmission, but must rely on enhanced neurotransmission after NMDAR-antagonist-induced plasticity, occurring at rest 18 . The observation of behavioural effects mediated through spontaneous neurotransmission provides the first evidence that tonic resting neurotransmission is involved in behaviour, and supports the notion that spontaneous and evoked forms of glutamatergic signalling are segregated 18, 23, 28, 29 . These data demonstrate that eEF2K inhibition, resulting in de-suppression of protein translation, is sufficient to produce antidepressant-like effects, implicating eEF2K inhibitors as potential novel major depressive disorder treatments with rapid onset. Moreover, our results show that synaptic translational machinery may serve as a viable therapeutic target for the development of faster-acting antidepressants.
METHODS SUMMARY
Behavioural studies were performed using adult male C57BL/6 wild-type or mutant mouse strains, maintained as previously described 10, 15 . All drugs were administered via intraperitoneal injection. Antidepressant-like behaviour was assessed using the forced swim test, as previously described 4 . Briefly, animals were placed in a cylinder of water at 22-24 uC for 6 min and immobility was measured during the last 4 min of the test. Molecular studies consisted of western blot analysis or quantitative PCR performed on whole-cell lysates from medial prefrontal cortex or anterior hippocampus. Electrophysiological studies were performed as previously described in cultured neurons (whole-cell recordings 23 ) or in hippocampal slices (field recordings 10 ).
METHODS
Mice. C57BL/6 male mice aged 6-8 weeks old were habituated to animal facilities for 1 week before behavioural testing. Mice were kept on a 12 h/12 h light/dark cycle and were given access to food and water ad libitium. Inducible Bdnf knockouts were generated from a trigenic cross of NSE-tTA, TetOp-Cre and floxed Bdnf mice, as previously described 10 . Conditional Ntrk2-knockout mice were made by crossing CamK-cre(93) (ref. 15 ) to floxed Ntrk2 mice. For all behavioural testing, male mice were 2-4 months old and weight-matched, and groups were balanced by genotype. All animal procedures conformed to the guide for the care and use of laboratory animals and were approved by the institutional animal care and use committee at UT Southwestern Medical Center. Drugs. All drugs were injected intraperitoneally. Concentrations were as follows: ketamine (Fort Dodge Animal Health) 3.0 mg kg 21 , MK-801 (Sigma) 0.1 mg kg 21 and CPP (Sigma) 0.5 mg kg 21 in 0.9% saline; anisomycin (Sigma) 100 mg kg 21 (dissolved in HCl/saline, final pH 7.4); actinomycin D (Sigma) 0.5 mg kg 21 in 5% ethanol; rottlerin and NH125 (Sigma) 5 mg kg 21 in 20-100% DMSO; SL327 (Sigma) 10 mg kg 21 in 100% DMSO 30 ; NMDA (Sigma) 75 mg kg 21 , NBQX (Sigma) 10 mg kg 21 and picrotoxin (Sigma) 1 mg kg 21 in 0.9% saline; rapamycin (Sigma) 1.0 mg kg 21 dissolved in 50% DMSO. Sucrose consumption test. Group-housed mice were habituated to a 1% solution of sucrose in tap-water for 48 h. The mice were then habituated to water-deprivation periods of 4 h, 14 h and 19 h, followed by a 1 h exposure to the sucrose solution for 3 days with intervening access to normal drinking water. To assess individual sucrose intake, the group-housed mice were water-deprived overnight and then housed temporarily in a new cage. Each test mouse was placed in its home cage for 1 h with access to the 1% sucrose solution. The bottle of sucrose solution was weighed before and after the test to determine sucrose intake. A water test was performed in a similar manner the following day. Data are expressed as a percentage of sucrose to total volume consumed in both sucrose and water trials. Context and cued fear conditioning. Fear conditioning was performed as previously described 5 . Briefly, mice were placed in individual chambers for 2 min, followed by a loud tone (90 dB) for 30 s, immediately followed by a 0.5 mA footshock for 2 s. After 1 min, mice received a second pairing of tone and footshock, as described. Mice were placed in home cages until 24 h later, when the mice were placed back in the same boxes without a tone or shock. The amount of time that the animal spent freezing was scored by an observer blind to genotype. Freezing behaviour was defined as no movement except for respiration. Four hours later, mice were placed in a novel environment with no tone or shock for 3 min, followed by 3 min of the tone to assess cue-dependent fear conditioning. Again, time spent freezing was recorded as described 10 The slices were rapidly frozen and lysed in buffer containing protease inhibitors and phosphatase inhibitors. Total protein concentration was quantified by Bradford analysis. BDNF quantification was carried out by SDS-polyacrylamide gel electrophoresis. Primary antibodies for BDNF (Santa Cruz Biotechnology) and GAPDH (Cell Signaling) were used at dilutions of 1:200 and 1:10,000, and antirabbit secondary antibodies were used at 1:2,000 and 1:50,000, respectively. To measure phosphorylated eEF2 (p-eEF2, Thr 56) and total eEF2, primary antibodies were used at dilutions of 1:1,000 and anti-rabbit secondary antibodies were used at 1:2,000. Mouse anti-ARC (C7, Cell Signaling) was used at a primary dilution of 1:1,000 and secondary dilution of 1:2,000. Phospho-mTOR and total mTOR (Cell Signaling) were both used at primary dilutions of 1:500 and secondary dilutions of 1:10,000. GluR1 (Chemicon) was used at a primary dilution of 1:5,000 and secondary dilution, 1:2,000. Pan-HOMER antibody (Cell Signaling) was used at 1:5,000 with 1:2,000 dilutions for primary and secondary, respectively. Phospho-s6 kinase and total s6 kinase antibodies were used at 1:200 and 1:5,000 for primary dilutions, respectively, and both had secondary dilutions of 1:5,000 (Cell Signaling). Phospho-MAPK and total MAPK antibodies (Cell Signaling) were used at primary dilutions of 1:10,000 and 1:500 respectively and both had secondary dilutions of 1:2,000. Bands developed with enzymatic chemiluminescence (ECL) were exposed to film and films were analysed by ImageJ. BDNF was normalized to GAPDH bands, and p-eEF2 and total eEF2 bands were taken as a ratio of GAPDH-normalized values.
Immunohistochemistry. C57BL/6 mice were treated intraperitoneally with saline, ketamine (3.0 mg kg 21 ) or MK-801 (0.1mg kg 21 ) and killed 30 min later. The protocol is adapted from a previous study 32 . Brains were fresh-dissected and fixed for 72 h in ice-cold 4% paraformaldehyde. Brains were cryoprotected for 2 or more hours in 20% glycerol, sectioned on a freezing microtome at 30 mm and preserved in 13 PBS with 0.01% sodium azide. Floating sections were washed in 23 SSC, followed by antigen-unmasking in 50:50 acetone:methanol, performed at 4 uC. Sections were rinsed and endogenous peroxidase activity was quenched in 1% H 2 O 2 for 30 min. Sections were rinsed in 23 SSC with 0.05% Tween-20. Tissue was blocked for 30 min in 3% normal goat serum diluted in 23 SSC/ 0.05% Tween, followed by primary antibody, rabbit anti-p-eEF2 (diluted 1:100 in blocking solution; Cell Signaling Technology), and incubation for 48 h at 4 uC. After rinsing in 23 SSC, a horseradish-peroxidase-labelled secondary antibody at 1:200 was applied and the signal was amplified using the tyramide amplification signal system (Perkin Elmer). Slides were counterstained with 49,6-diamidino-2phenylindole (DAPI), mounted on superfrost plus slides, dried for 2 h and mounted in DPX mountant. ELISA. A high-sensitivity enzyme-linked immunosorbent assay was used to assess BDNF levels, as per manufacturer's instructions (Promega). Briefly, hippocampal lysates were prepared in the recommended buffer, diluted 1:4 in 13 PBS and acidtreated as instructed by the manufacturer. A 96-well plate (Nunc) was coated overnight in carbonate coating buffer, blocked in the provided sample buffer for
